Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study

被引:60
|
作者
Ramm-Pettersen, Anette [1 ]
Nakken, Karl O. [1 ]
Skogseid, Inger M. [2 ]
Randby, Hans [3 ]
Skei, Erik B. [4 ]
Bindoff, Laurence A. [5 ,6 ]
Selmer, Kaja K. [7 ,8 ]
机构
[1] SSE, Dept Refractory Epilepsy, Oslo, Norway
[2] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[3] Vestfold Hosp Trust, Dept Pediat, Tonsberg, Norway
[4] Akershus Univ Hosp, Dept Pediat, Lorenskog, Norway
[5] Univ Bergen, Dept Clin Med, Bergen, Norway
[6] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway
[7] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway
[8] Univ Oslo, Inst Med Genet, Oslo 3, Norway
关键词
MODIFIED ATKINS DIET; BLOOD-BRAIN-BARRIER; GLUCOSE-TRANSPORT; EPILEPSY; SPECTRUM; INHERITANCE; MUTATIONS; SEIZURES; FEATURES; SLC2A1;
D O I
10.1111/dmcn.12096
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim The aim of this study was to characterize patients diagnosed with glucose transporter protein-1 deficiency syndrome (GLUT-1 DS) clinically and genetically, and to evaluate the effect of treatment with the classic ketogenic or modified Atkins diet. Method We retrospectively studied medical records of 10 patients diagnosed with GLUT-1 DS. Four females and six males with a median age of 15years were included. Results The study illustrates the genetic and clinical heterogeneity of GLUT-1 DS. Analysis of the SLC2A1 gene disclosed a variety of mutation types. The time between onset of symptoms and diagnosis was more than 11years on average. The outcome in those with early diagnosis and intervention was surprisingly good. All but one patient with the classic phenotype became seizure free after treatment with the classic ketogenic or modified Atkins diet. Acetazolamide was effective in one patient with paroxysmal exercise-induced dyskinesia. A point prevalence of GLUT-1 DS in Norway was estimated as 2.6 per 1000000 inhabitants. Interpretation Although the long-term prognosis in patients with GLUT-1 DS partly depends on the underlying genetics, our study supports the assumption that early initiation of treatment with a ketogenic diet may positively affect the outcome.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 14 条
  • [1] Individualizing Treatment Approaches for Epileptic Patients with Glucose Transporter Type1 (GLUT-1) Deficiency
    Daci, Armond
    Bozalija, Adnan
    Jashari, Fisnik
    Krasniqi, Shaip
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (01)
  • [2] Use of dietary therapies amongst patients with GLUT1 deficiency syndrome
    Kass, Hannah R.
    Winesett, S. Parrish
    Bessone, Stacey K.
    Turner, Zahava
    Kossoff, Eric H.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2016, 35 : 83 - 87
  • [3] Uncovering microdeletions in patients with severe Glut-1 deficiency syndrome using SNP oligonucleotide microarray analysis
    Levy, Brynn
    Wang, Dong
    Ullner, Paivi M.
    Engelstad, Kristin
    Yang, Hong
    Nahum, Odelia
    Chung, Wendy K.
    De Vivo, Darryl C.
    MOLECULAR GENETICS AND METABOLISM, 2010, 100 (02) : 129 - 135
  • [4] GLUT1 Deficiency Syndrome-Early Treatment Maintains Cognitive Development? (Literature Review and Case Report)
    Kolic, Ivana
    Nisevic, Jelena Radic
    Cicvaric, Inge Vlasic
    Ahel, Ivona Butorac
    Tomulic, Kristina Lah
    Segulja, Silvije
    Dekanic, Kristina Baraba
    Serifi, Senada
    Ovuka, Aleksandar
    Prpic, Igor
    GENES, 2021, 12 (09)
  • [5] Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study
    De Giorgis, Valentina
    Bhatia, Kailash P.
    Boespflug-Tanguy, Odile
    Gras, Domitille
    Marina, Adela Della
    Desurkar, Archana
    Toledo, Manuel
    Miller, Ian
    Rotstein, Michael
    Schneider, Susanne A.
    Tarquinio, Daniel C.
    Weber, Yvonne
    Brandabur, Melanie
    Mayhew, Jill
    Koutsoukos, Tony
    De Vivo, Darryl C.
    MOVEMENT DISORDERS, 2024, 39 (08) : 1386 - 1396
  • [6] Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory framework
    Zovi, Andrea
    Cifani, Carlo
    Confalonieri, Corrado
    Lasala, Ruggero
    Sabbatucci, Michela
    Vitiello, Antonio
    Vittori, Sauro
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2024, 78 (12) : 1058 - 1063
  • [7] Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019
    Czogala, Malgorzata
    Pawinska-Wasikowska, Katarzyna
    Ksiazek, Teofila
    Sikorska-Fic, Barbara
    Matysiak, Michal
    Skalska-Sadowska, Jolanta
    Wachowiak, Jacek
    Rodziewicz-Konarska, Anna
    Chybicka, Alicja
    Myszynska-Roslan, Katarzyna
    Krawczuk-Rybak, Maryna
    Grabowski, Dominik
    Kowalczyk, Jerzy
    Maciejka-Kemblowska, Lucyna
    Adamkiewicz-Drozynska, Elzbieta
    Bobeff, Katarzyna
    Mlynarski, Wojciech
    Tomaszewska, Renata
    Szczepanski, Tomasz
    Pohorecka, Joanna
    Chodala-Grzywacz, Agnieszka
    Karolczyk, Grazyna
    Mizia-Malarz, Agnieszka
    Mycko, Katarzyna
    Badowska, Wanda
    Zielezinska, Karolina
    Urasinski, Tomasz
    Nykiel, Magdalena
    Woszczyk, Mariola
    Ciebiera, Malgorzata
    Chaber, Radoslaw
    Skoczen, Szymon
    Balwierz, Walentyna
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [8] Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study
    Nikanorova, Marina
    Brandt, Christian
    Auvin, Stephane
    McMurray, Rob
    EPILEPSY & BEHAVIOR, 2017, 76 : 63 - 70
  • [9] Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China
    Fan, Chengjuan
    Jin, Guangxin
    Sun, Chen
    Ma, Donglai
    Chen, Chongyan
    Qiao, Pengfei
    Wu, Dequan
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2014, 26 (02) : 123 - 130
  • [10] Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort
    Gamba, Anna
    Depascale, Roberto
    Zanatta, Elisabetta
    Ienna, Luana
    Cruciani, Claudio
    Gatto, Mariele
    Zen, Margherita
    Doria, Andrea
    Iaccarino, Luca
    CLINICAL RHEUMATOLOGY, 2024, 43 (10) : 3167 - 3174